Evaluation of pulmonary side effects in prolactinoma patients treated with cabergoline.

IF 2 4区医学 Q3 ENDOCRINOLOGY & METABOLISM Endokrynologia Polska Pub Date : 2023-08-14 DOI:10.5603/EP.a2023.0045

Ozlem Soyluk, Zuleyha Bingol, Sema Ciftci, Neslihan Kurtulmus, Seher Tanrikulu, Sema Yarman

{"title":"Evaluation of pulmonary side effects in prolactinoma patients treated with cabergoline.","authors":"Ozlem Soyluk, Zuleyha Bingol, Sema Ciftci, Neslihan Kurtulmus, Seher Tanrikulu, Sema Yarman","doi":"10.5603/EP.a2023.0045","DOIUrl":null,"url":null,"abstract":"Introduction: Cabergoline (CAB) is the most used dopamine agonist in the treatment of prolactinomas. Studies related to the treatment of Parkinson's disease have shown that dopamine agonists can lead to fibrotic syndromes affecting the heart and the lung. The aim of this study was to evaluate the possible pulmonary side effects of CAB in prolactinoma patients.Material and methods: Chest X-ray imaging and pulmonary function parameters like forced vital capacity (FVC), total lung capacity (TLC), and diffusion capacity for carbon monoxide (DLCO) were evaluated in 73 prolactinoma patients. The cumulative dose of CAB and the total duration of CAB use were also calculated, and all data were reviewed retrospectively.Results: The median cumulative CAB dose was 192 mg, and the median duration of CAB use was 64 months. Only 13 patients (17%) among this cohort had abnormal DLCO results that could be an indirect sign of pulmonary fibrosis. These abnormal DLCO results were found not to be associated with cumulative CAB dose in these 13 patients.Conclusions: CAB appears to be safe in terms of pulmonary functions with a median cumulative dose of 192 mg in prolactinoma patients.","PeriodicalId":11551,"journal":{"name":"Endokrynologia Polska","volume":" ","pages":""},"PeriodicalIF":2.0000,"publicationDate":"2023-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Endokrynologia Polska","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5603/EP.a2023.0045","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Cabergoline (CAB) is the most used dopamine agonist in the treatment of prolactinomas. Studies related to the treatment of Parkinson's disease have shown that dopamine agonists can lead to fibrotic syndromes affecting the heart and the lung. The aim of this study was to evaluate the possible pulmonary side effects of CAB in prolactinoma patients.

Material and methods: Chest X-ray imaging and pulmonary function parameters like forced vital capacity (FVC), total lung capacity (TLC), and diffusion capacity for carbon monoxide (DLCO) were evaluated in 73 prolactinoma patients. The cumulative dose of CAB and the total duration of CAB use were also calculated, and all data were reviewed retrospectively.

Results: The median cumulative CAB dose was 192 mg, and the median duration of CAB use was 64 months. Only 13 patients (17%) among this cohort had abnormal DLCO results that could be an indirect sign of pulmonary fibrosis. These abnormal DLCO results were found not to be associated with cumulative CAB dose in these 13 patients.

Conclusions: CAB appears to be safe in terms of pulmonary functions with a median cumulative dose of 192 mg in prolactinoma patients.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

卡麦角林治疗催乳素瘤患者肺部副反应的评价。

卡麦角林(Cabergoline, CAB)是治疗催乳素瘤最常用的多巴胺激动剂。与帕金森病治疗相关的研究表明，多巴胺激动剂可导致影响心脏和肺部的纤维化综合征。本研究的目的是评估CAB在催乳素瘤患者中可能出现的肺部副作用。材料与方法:对73例催乳素瘤患者的胸部x线影像及用力肺活量(FVC)、总肺活量(TLC)、一氧化碳弥散量(DLCO)等肺功能参数进行评价。还计算了CAB的累积剂量和CAB使用的总持续时间，并对所有数据进行回顾性回顾。结果:CAB的中位累积剂量为192 mg, CAB的中位持续时间为64个月。该队列中只有13例患者(17%)DLCO结果异常，这可能是肺纤维化的间接迹象。在这13例患者中，发现这些异常的DLCO结果与累积CAB剂量无关。结论:在泌乳素瘤患者中，CAB的中位累积剂量为192 mg，在肺功能方面似乎是安全的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Endokrynologia Polska ENDOCRINOLOGY & METABOLISM-

CiteScore

2.60

自引率

9.50%

发文量

129

审稿时长

6-12 weeks

期刊介绍： "Endokrynologia Polska" publishes papers in English on all aspects of clinical and experimental endocrinology. The following types of papers may be submitted for publication: original articles, reviews, case reports, postgraduate education, letters to the Editor (Readers’ Forum) and announcements of scientific meetings, conferences and congresses.